Anticancer drug-induced EGFR kinase silencing may thus cause CRC response via a compensatory FGFR2b-mediated JNK1 and IL-1 signal which occurs against a background of p53 upregulation and TAp63α expression. Here, TP53 is linked to colorectal carcinoma.